ダウンロード数: 25
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
j.ensci.2021.100351.pdf | 896.29 kB | Adobe PDF | 見る/開く |
タイトル: | A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus |
著者: | Shima, Atsushi https://orcid.org/0000-0002-3068-4621 (unconfirmed) Maki, Takakuni Mimura, Naoya Yamashita, Hirofumi Emoto, Noriaki Yoshifuji, Hajime Takahashi, Ryosuke https://orcid.org/0000-0002-1407-9640 (unconfirmed) |
著者名の別形: | 島, 淳 眞木, 崇州 三村, 直哉 山下, 博史 吉藤, 元 髙橋, 良輔 |
キーワード: | Cilostazol Lomerizine Anti-phospholipid antibody syndrome Reversible cerebral vasoconstriction syndrome Endothelin-1 |
発行日: | Sep-2021 |
出版者: | Elsevier BV |
誌名: | eNeurologicalSci |
巻: | 24 |
論文番号: | 100351 |
抄録: | The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective. |
著作権等: | © 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. |
URI: | http://hdl.handle.net/2433/276959 |
DOI(出版社版): | 10.1016/j.ensci.2021.100351 |
PubMed ID: | 34258413 |
出現コレクション: | 学術雑誌掲載論文等 |
このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス